Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Raloxifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 20/20 | 1.00 |
| ▸ | ESR2 known ✓ | Q92731 | 19/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | HLA-A | P04439 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | UBE2N | P61088 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | PLD2 | O14939 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Raloxifene SCHEMBL178172 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL1665291 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL9201404 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL19077 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL7631648 | 0.99 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL975023 | 0.99 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL3162158 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Ly-117018 SCHEMBL7080240 | 0.99 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL6144 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL9145135 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2815236-A1 | MEANS AND METHODS FOR ASSESSING AN ENDOCRINE DISEASE OR DISORDER | BASF SE (DE) | 2014-12-24 | — | — | EP | disclosed |
| WO-2014036520-A1 | COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS | MERRIMACK PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| EP-2678359-A2 | COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS | Merrimack Pharmaceuticals, Inc. (US) | 2014-01-01 | — | — | EP | disclosed |
| WO-2013121380-A1 | MEANS AND METHODS FOR ASSESSING AN ENDOCRINE DISEASE OR DISORDER | BASF SE (DE) | 2013-08-22 | — | — | WO | disclosed |
| WO-2012116317-A2 | COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS | MERRIMACK PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | WO | disclosed |